High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study Jae-Ho Yoon, Hee-Je Kim * , Dae-Hun Kwak, Sung-Soo Park, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee and Woo-Sung Min Abstract: Wilms' tumor gene 1 (WT1) expression is a well-known predictor for relapse in acute myeloid leukemia. We monitored WT1 decrement along the treatment course to identify its significant role as a marker for residual disease in acute promyelocytic leukemia (APL) and tried to suggest its significance for relapse prediction. In this single center retrospective study, we serially measured PML-RARa and WT1 expression from 117 APL patients at diagnosis, at post-induction and post-consolidation chemotherapies, and at every 3 months after starting maintenance therapy. All 117 patients were in molecular remission after treatment of at least 2 consolidation chemotherapies. We used WT1 ProfileQuant™ kit (Ipsogen) for WT1 monitoring. High WT1 expression (>120 copies/10 4 ABL1) after consolidation and at early period (3 months) after maintenance therapy significantly predicted subsequent relapse. All paired PML-RARa RQ-PCR were not detected except for one sample with early relapse. Patients with high WT1 expression at 3 months after maintenance therapy (n = 40) showed a significantly higher relapse rate (30.5 vs. 6.9%, P < 0.001) and inferior disease free survival (62.8 vs. 91.4%, P < 0.001). Multivariate analysis revealed that high peak leukocyte counts at diagnosis (HR = 6.4, P < 0.001) and high WT1 expression at 3 months after maintenance therapy (HR = 7.1, P < 0.001) were significant factors for prediction of relapse. Our data showed high post-remission WT1 expression was a reliable marker for prediction of subsequent molecular relapse in APL. In this high-risk group, early intervention with ATRA ± ATO, anti-CD33 antibody therapy, and WT1-specific therapy may be used for relapse prevention.
Findings
In acute promyelocytic leukemia (APL), PML-RARa transcript is used as a marker for minimal residual disease (MRD), but the marker is not useful for pre-emptive management since its positivity directly indicates relapse. High Wilms' tumor gene 1 (WT1) expression was related with subsequent relapse in acute myeloid leukemia, and Hecht et al. recently reported that high initial WT1 expression was associated with more relapse in APL [1] [2] [3] .
We confirmed APL by chromosome analysis and PML-RARα reverse transcriptase polymerase chain reaction (RT-PCR) method. All were treated with idarubicin (12 mg/m 2 , days 1, 3, 5, and 7) and all-trans retinoic acid (ATRA; 45 mg/m 2 /day) [4, 5] . After achievement of hematological complete remission (CR), all received three courses of consolidation-first, idarubicin (7 mg/m 2 , days 1-4); second, mitoxantrone (10 mg/m 2 , days 1-4); and third, idarubicin (12 mg/m 2 , day 1-2)-followed by 2-year maintenance using 6-mercaptopurine (50 mg/m 2 / day) plus ATRA [5] [6] [7] . The molecular studies were performed at diagnosis and 1 month after chemotherapy, and every 3 months after maintenance. Quantification of PML-RARα and WT1 were performed using the realtime quantitative (RQ)-PCR methods (Real-Q PML-RARα quantification kit, Biosewoom, Korea, and WT1 ProfileQuant™ kit, Ipsogen, France) presenting a similar sensitivity of 4.5 log.
We initially identified 142 APL patients from 2009 to 2014 but finally focused on 117 patients (median age 44 years old (range 19-70 years)) who underwent at least 2 cycles of consolidation after hematological CR. All patients were in complete molecular response (CMR) at the time of enrollment (Additional file 1: Figure S1 , Table 1 ). Relapse was identified in 16 (13.7%) patients with a median duration of 22.8 months (range, 4.3-64.0). After median follow-up of 46.0 months (range, 14.7-86.3), 4-year cumulative incidence of relapse (CIR), non-relapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) rates were 16.2, 1.2, 82.6, and 92.5%, respectively. We identified that high-risk Sanz-criteria, peak leukocyte count >40.0 × 10 9 /L, and FLT3 mutation were predictive for relapse. We compared the level of WT1 between relapsed and non-relapsed group during the course of treatment (Additional file 1: Figure S2 ) and identified that median WT1 was significantly different at post 2nd consolidation (171.5 vs. 76.3, P = 0.049), at post 3rd consolidation (156.0 vs. 67.6, P = 0.013) and at 3 months postmaintenance (162.0 vs. 59.1, P = 0.002). We found that WT1 post-maintenance 3 months was the most significant parameter for relapse prediction at the cutoff of ≥120.0 copies/10 4 ABL. We calculated subsequent CIR and DFS rates in 116 patients after excluding 1 patient with early relapse. Patients with WT1 post-maintenance 3 months higher than 120.0 copies/10 4 ABL showed higher 4-year CIR (30.5 vs. 6.9%, P = 0.0002) and inferior 4-year DFS (62.8 vs. 91.4%, P < 0.0001) rates (Fig. 1a, b) . Also in the high-risk subgroup, high WT1 post-maintenance 3 months showed higher 4-year CIR (43.3 vs. 11.1%, P < 0.0001) and inferior 4-year DFS (55.5 vs. 86.4%, P = 0.0015) rates (Fig. 1c, d) . In FLT3 positive and negative subgroup, high WT1 post-maintenance 3 months showed higher 4-year CIR (51.4 vs. 0.0%, P < 0.0001 and 21.5 vs. 8.6%, P = 0.0434) and inferior 4-year DFS (46.7 vs. 100.0%, P = 0.0018 and 69.6 vs. 89.3%, P = 0.0154) rates (Fig. 1e, f ) .
Multivariate analysis (Additional file 1: Table S1 ) revealed that 4-year CIR was significantly higher in patients with high peak leukocyte count (HR = 6.414; 95% CI, 2.1-19.3, P < 0.001) and high WT1 post-maintenance 3 month (HR = 7.533; 95% CI, 2.3-24.8, P < 0.001), and 4-year DFS was significantly inferior in patients with high peak leukocyte count (HR = 5.275; 95% CI, 1.9-14.7, P = 0.001) and high WT1 post-maintenance 3 month (HR = 8.241; 95% CI, 2.3-29.1, P = 0.001).
Unfortunately, our chemotherapy regimen was not differently specified for high-risk APL and the standard treatment of APL is now changed to a combination therapy using ATO. Therefore, current results may not be applicable in the treatment course using ATO and another validation is needed. Conclusively, high post-remission WT1 expression is a reliable marker for prediction of subsequent relapse in APL patients treated with conventional chemotherapy. For patients with high-risk of relapse, early intervention using WT1-specific therapy may prevent relapse and improve survival outcomes [8, 9] .
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